Место фиксированной комбинациифенотерола и ипратропиума в терапиихронических обструктивныхзаболеваний легких

1. Авдеев С.Н., Нуралиева Г.С., Батын С.З., Чучалин А.Г. Эффективность терапии Беродуалом Н с помощью малых спейсеров при обострении обструктивных болезней легких. Пульмонология 2005; 6: 86–90.
2. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542–9.
3. Berger R, Smith D. Effect of inhaled metaproterenol on exercise performance in patients with stable «fixed» airway оbstruction. Am Rev Respir Dis 1988; 138(3): 624–9.
4. Hay JG, Stone P, Carter J et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992; 5(6): 659–64.
5. Liu CL, Lu YT. Bronchodilatation effects of a small volume spacer used with a metered-dose inhaler. J Asthma 2009; 46(7): 637–41.
6. Molimard M, Raherison C, Lignot S et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16(3): 249–54.
7. Глобальная стратегия лечения и профилактики бронхиальной астмы. Под ред. А.Г.Чучалина. М.: Издательский дом «Атмосфера», 2007.
8. Global Strategy for Diagnosis, Management, and Prevention of COPD. Global Initiative for COPD (GOLD), 2009. www.goldcopd.com
9. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000; 161(6): 1862–8.
10. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59(5): 469–78.
11. Lopez AD, Murray CC. The global burden of disease, 1990–2020. Nat Med 1998; 4(11): 1241–3.
12. Cazzola M. Current opinion: Pharmacological approaches in asthma and COPD. Breath 2009; 6(1): 25–35.
13. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374(9691): 733–43.
14. Appleton S, Jones T, Poole P et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 2: CD001387.
15. Vincken W, van Noord JA, Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209–16.
16. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
17. Kerstjens HA, Bantje TA, Luursema PB et al. Effects of short-acting bronchodilators added to maintenance tiotropium therapy. Chest 2007; 132(5): 1493–9.
18. Chrischilles E, Gilden D, Kubisiak J et al. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am J Manag Care 2002; 8(10): 902–11.
19. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64(8): 728–35.
20. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006; 533: 36–9.
21. Cazzola M, Matera MG, Donner CF. Inhaled β2-adrenoreceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65: 1595–610.
22. Маколкин В.И., Овчаренко С.И., Передельская О.А., Акскльрод А.С. Эффект высоких доз бронхолитиков на состояние сердечно-сосудистой системы во время лечения тяжелых обострений бронхиальной астмы. Кардиология 2004. 2: 65–9.